Peptide-based weight loss therapies have transformed the obesity treatment market. The global obesity epidemic continues to rise, with the World Health Organization estimating that more than 1 billion people worldwide are living with obesity. In the United States alone, nearly 40% of adults are obese, creating enormous demand for effective weight management therapies.
Today, two companies dominate the peptide weight loss market: Eli Lilly and Company and Novo Nordisk. Their GLP-1 and dual-incretin peptide therapies have generated record-breaking sales and reshaped the pharmaceutical industry.
1. Eli Lilly and Company
Eli Lilly has emerged as the world’s leading peptide company for weight loss. Its flagship peptide, tirzepatide, is marketed as Zepbound for obesity and Mounjaro for diabetes.
Clinical trials have shown that tirzepatide can help patients lose more than 20% of body weight, making it one of the most effective obesity treatments ever developed.
The company reported total revenue of $65.2 billion in 2025, representing 45% annual growth. Zepbound alone generated $13.5 billion in sales during 2025, while Mounjaro contributed nearly $23 billion. Together, these products accounted for over half of Lilly’s total revenue.
Key Weight Loss Products
- Zepbound (tirzepatide)
- Mounjaro (tirzepatide)
- Orforglipron (oral obesity candidate)
- Retatrutide (late-stage obesity candidate)
Consumer Demand
Lilly’s GLP-1 portfolio generated approximately $12.9 billion in sales during Q1 2026 alone. Analysts estimate Lilly controls more than 60% of the U.S. incretin market and nearly 70% of new branded obesity prescriptions.
Eli Lilly Statistical Snapshot
| Metric | Value |
|---|---|
| 2025 Revenue | $65.2 Billion |
| 2025 Zepbound Sales | $13.5 Billion |
| 2025 Mounjaro Sales | $23.0 Billion |
| Q1 2026 GLP-1 Sales | $12.9 Billion |
| U.S. Obesity Prescription Share | ~70% |
| Revenue Growth (2025) | 45% |
Why Lilly Leads
Lilly’s success comes from superior weight-loss outcomes, massive manufacturing investments, expanding insurance coverage, and strong physician adoption.
Industry analysts consider Zepbound the fastest-growing obesity drug in pharmaceutical history.
Want to see the in depth market opportunities, competitor strategies, and statistical insights shaping your industry? Download a FREE customized sample report: https://www.towardshealthcare.com/download-sample/6114
2. Novo Nordisk
Novo Nordisk pioneered the modern peptide weight loss market through semaglutide-based therapies.
The company developed Wegovy, the first blockbuster obesity peptide that demonstrated substantial weight reduction while improving cardiovascular outcomes.
Wegovy became a global phenomenon, with demand significantly exceeding manufacturing capacity across several markets.
Key Weight Loss Products
- Wegovy (semaglutide)
- Ozempic (semaglutide)
- Saxenda (liraglutide)
- Amycretin (pipeline candidate)
Market Position
Novo Nordisk remains one of the largest obesity-focused pharmaceutical companies globally.
According to market tracking studies, Wegovy remains among the most recognized weight loss brands worldwide and continues to dominate physician awareness and consumer demand.
Novo Nordisk Statistical Snapshot
| Metric | Value |
|---|---|
| Flagship Weight Loss Drug | Wegovy |
| Active Ingredient | Semaglutide |
| Global Brand Recognition | Industry Leading |
| Major Obesity Brands | Wegovy, Saxenda |
| Market Position | Global Top 2 |
| Primary Focus | Obesity & Diabetes |
Why Novo Nordisk Matters
Novo Nordisk essentially created the commercial obesity-drug market. Wegovy demonstrated that peptide therapies could produce double-digit weight loss, opening the door for the entire GLP-1 revolution.
Although Lilly has recently gained market share, Novo Nordisk remains one of the most trusted names in obesity treatment worldwide.
Industry Statistics
| Market Indicator | Value |
|---|---|
| Global Adults Living with Obesity | 1+ Billion |
| U.S. Adult Obesity Rate | ~40% |
| Leading Drug Class | GLP-1 Peptides |
| Fastest Growing Segment | Obesity Therapeutics |
| Dominant Companies | Eli Lilly & Novo Nordisk |
| Weight Loss Potential | Up to 20%+ Body Weight |
3. Amgen Inc.
Amgen is one of the largest biotechnology companies actively competing in the obesity peptide market. While the company entered the weight-loss segment later than Eli Lilly and Novo Nordisk, it has rapidly gained investor attention through its obesity candidate MariTide (maridebart cafraglutide).
Clinical studies have shown that MariTide can produce significant weight loss with less frequent dosing, potentially offering a competitive advantage over weekly GLP-1 therapies. The company is investing heavily in obesity research as global demand for peptide-based weight management solutions continues to rise.
Amgen reported approximately $34.1 billion in total revenue during 2025. Although MariTide is still under development, analysts consider it one of the most promising next-generation obesity therapies in the pharmaceutical pipeline.
Key Weight Loss Products
- MariTide (Maridebart Cafraglutide)
- Obesity Pipeline Programs
- Metabolic Disease Research Portfolio
Market Position
Amgen is leveraging its strong biologics expertise and manufacturing infrastructure to enter the obesity market. Industry forecasts suggest that successful commercialization of MariTide could generate multi-billion-dollar annual sales during the next decade.
The company’s obesity program has become one of the most closely watched developments among investors and healthcare providers.
Amgen Statistical Snapshot
| Metric | Value |
|---|---|
| 2025 Revenue | $34.1 Billion |
| Headquarters | California, USA |
| Lead Obesity Candidate | MariTide |
| Clinical Stage | Phase 3 |
| Weight Loss Market Focus | Obesity & Metabolic Diseases |
| Global Employees | 28,000+ |
Why Amgen Matters
Amgen possesses extensive biologics manufacturing capabilities and global commercialization experience. If MariTide achieves regulatory approval, the company could become one of the largest competitors to Eli Lilly and Novo Nordisk in the obesity peptide market.
4. Roche Holding AG
Roche has emerged as a major obesity market contender following its strategic investments and acquisitions focused on next-generation peptide therapies.
The company expanded its obesity portfolio through licensing agreements and acquisitions involving GLP-1 and incretin-based drug candidates. Roche aims to establish a significant presence in the rapidly growing obesity therapeutics market, which analysts estimate could exceed $150 billion annually by the mid-2030s.
Roche generated approximately $71 billion in revenue during 2025, making it one of the world’s largest healthcare companies. The company is leveraging its substantial R&D resources to accelerate obesity drug development.
Key Weight Loss Products
- CT-388 (Dual GLP-1/GIP Agonist)
- Obesity Research Programs
- Metabolic Disease Pipeline
Market Position
Roche’s obesity strategy focuses on developing differentiated therapies capable of providing superior weight-loss outcomes and improved patient convenience.
Industry experts believe Roche’s extensive global presence and financial strength position it as a potential future leader in obesity therapeutics.
Roche Statistical Snapshot
| Metric | Value |
|---|---|
| 2025 Revenue | $71 Billion |
| Headquarters | Switzerland |
| Lead Obesity Candidate | CT-388 |
| Market Focus | Obesity & Metabolic Diseases |
| Global Employees | 100,000+ |
| Annual R&D Spending | $14+ Billion |
Why Roche Matters
Roche has one of the largest pharmaceutical research budgets globally. Its ability to acquire innovative obesity assets and rapidly scale commercialization efforts makes it a serious competitor in the peptide weight-loss industry.
Updated Industry Rankings for Weight Loss Peptide Companies
| Rank | Company | Leading Product |
|---|---|---|
| 1 | Eli Lilly and Company | Zepbound |
| 2 | Novo Nordisk | Wegovy |
| 3 | Amgen Inc. | MariTide |
| 4 | Roche Holding AG | CT-388 |
| 5 | AstraZeneca | ECC5004 |
| 6 | Viking Therapeutics | VK2735 |
The peptide weight-loss market is experiencing unprecedented growth, driven by rising obesity rates, increasing healthcare spending, and strong clinical outcomes. According to industry estimates, the global obesity drug market is expected to surpass $150 billion by 2035.
While Eli Lilly and Novo Nordisk currently dominate commercial sales, companies such as Amgen and Roche are investing billions of dollars in next-generation peptide therapies. These firms are expected to intensify competition and drive further innovation in obesity treatment.
As peptide science advances, future therapies may offer greater weight reduction, fewer side effects, oral administration options, and improved long-term adherence, making the sector one of the fastest-growing areas in global pharmaceuticals.
About Us
Healthcare WebWire is a part of Towards Healthcare Research and Consulting is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.
Quick Contact Links
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium